TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04206540

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Auricular Vagus Nerve Stimulation
Description: Electrical stimulation of the vagus nerve around the external ear using a transcutaneous device. Electrical current will be increased in intensity based on subject feedback of a scale 0-10.~Electrical stimulation will be delivered for 2 minutes once the subject reports the maximum comfortable intensity.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vagal Stimulation
Description: Subjects will be asked to do the following in order to stimulate the vagus nerve:~* Cough 6 to 8 forceful coughs~* Have an ice cold wash cloth placed on their face for 10 seconds.~* Carotid massage~* Gagging: a tongue depressor is briefly inserted into the back of the mouth touching the bag of the throat.~* Valsalva maneuver: Subjects will be asked to bear down as if having a bowel movement. They will be asked to blow through a mouthpiece that is hooked to a device that measures how hard they are blowing. Alternatively, we can have them blow through the barrel of a 10 ml syringe for 15-20 seconds.~* Eating: Subjects will be asked to drink water and/or Ensure that has 220 calories after fasting overnight.
Study: NCT03942289

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The role of the noradrenergic system across the life span (Healthy Subjects)
Description: A sample (n=90) of balanced distribution of healthy males and females within a continuous segment of the adult life span from 20 to 80 years old will be recruited, with approximately 7 males and 7 females subjects for each decade of age. Each participant will undergo 1) a neuropsychological examination, 2) an olfactory screening and 3) a 90 min 11C-Yohimbine positron emission tomography (PET)/magnetic resonance imaging (MRI) scan in a resting state.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The role of the noradrenergic system across the life span (Parkinson's Disease Subjects)
Description: Three groups of Parkinson Disease (PD) patients (each of them n=15) will be studied according to the duration and stage of the disease: early stage (the same group in Task 2); mid stage (5-7 years of disease duration; Hoehn and Yahr in Off 2-3); late stage (7-10 years of disease duration; Hoehn and Yahr in Off 3-4).
Study: NCT06103396

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Transplantation of autologous MSCs in nonunion fracture
Description: At surgery, fibrotic tissue is removed from the nonunion sites. MSCs/Col/PRP clots are implanted in the site of nonunion.~Patients received conventional orthopedic treatment as they needed (osteotomy, external and/or internal fixation systems, etc.)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Transplantation of allogeneic MSCs in nonunion fracture
Description: At surgery, fibrotic tissue is removed from the nonunion sites. MSCs/Col/PRP clots are implanted in the site of nonunion.~Patients received conventional orthopedic treatment as they needed (osteotomy, external and/or internal fixation systems, etc.)
Study: NCT02149381

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBASP
Description: Cognitive behavioral group intervention for individuals suffering from chronic depression

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBASP
Description: Cognitive behavioral group intervention for individuals suffering from chronic depression

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBASP
Description: Cognitive behavioral group intervention for individuals suffering from chronic depression

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Befriending
Description: Social support intervention, sessions once per week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Conventional psychiatric outpatient treatment (individual counseling)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Conventional psychiatric outpatient treatment (individual counseling)
Study: NCT03272750

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bioscalin® new formulation with Galeopsis Segetum
Description: Total duration of the study was 4 months; each subject, took by mouth two capsules/die of placebo at breakfast and one tablet/die of study product at lunch for the first 3 months of the trial.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Reference product
Description: Total duration of the study was 4 months; each subject, took by mouth two capsules/die of reference product at breakfast and one tablet/die of placebo at lunch for the first 3 months of the trial.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Total duration of the study was 4 months; each subject, took by mouth two capsules/die of placebo at breakfast and one tablet/die of placebo at lunch for the first 3 months of the trial.
Study: NCT04239898

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red cabbage microgreens
Description: 2 cups per day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red beet microgreens
Description: 2 cups per day
Study: NCT04472052

Intervention type: OTHER
Intervention: appendectomy
Description: Surgical standard treatment for acute appendicitis All patients receive preoperative single-shot antibiosis, usually 2000 mg cefotaxime combined 500 mg metronidazole. Appendectomy is performed usually within 24 h of admission in patients with acute appendicitis. The laparoscopic appendectomy using the 3-trocar technique represents the surgical standard. In uncomplicated or non-perforated appendicitis, drainage is generally not required. Wounds are closed intra-cutaneous with absorbable sutures. Patients without postoperative complications are discharged home two days after surgery.
Study: NCT06119126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SDF1
Description: Topical SDF application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SDF1
Description: Topical SDF application

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diode Laser
Description: Irradiating Enamel by Diode laser

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diode Laser
Description: Irradiating Enamel by Diode laser

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pit Fissure Sealant
Description: Sealing occlusal pits and fissures

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pit Fissure Sealant
Description: Sealing occlusal pits and fissures
Study: NCT02552966

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UESAD
Description: Device designed to provide modest cricoid pressure to reduce reflux
Study: NCT04320004

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Subject receives education

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education with Reminder
Description: Subject receives education with reminder

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education + Disposal Bag
Description: Subject receives education and disposal bag

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education + Disposal Bag with Reminder
Description: Subject receives education + disposal bag with reminder
Study: NCT00056095

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation

Intervention type: PROCEDURE
Group type: OTHER
Intervention: allogeneic bone marrow transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation

Intervention type: PROCEDURE
Group type: OTHER
Intervention: peripheral blood stem cell transplantation
Study: NCT01643668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan as part of reduced intensity conditioning prior to allogeneic stem cell transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Clofarabine as part of reduced intensity conditioning prior to allogeneic stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Stem Cell Infusion
Description: Allogeneic stem cell transplantation after reduced intensity conditioning with busulfan / clofarabine chemotherapy
Study: NCT04835844

Intervention type: DEVICE
Intervention: CARTO
Description: Redo-ablation of paroxysmal AF with high density mapping system, CARTO, in conjunction with CONFIDENSE mapping module and PENTARRAY catheter

Intervention type: DEVICE
Intervention: RHYTHMIA
Description: Redo-ablation of paroxysmal AF with high density mapping system, RHYTHMIA, in conjunction with the 64-electrodes ORION mini-basket catheter.
Study: NCT02578407

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: accommodative/vergence therapy
Description: 12 weekly accommodative/vergence therapies
Study: NCT02719808

Intervention type: DRUG
Intervention: Tenofovir1
Description: receive tenofovir （300mg/d）from （28±2）weeks of pregnancy to one month after delivery, it is the observational exposure.

Intervention type: DRUG
Intervention: Tenofovir2
Description: receive tenofovir （300mg/d）from（28±2）weeks of pregnancy to one month after delivery, it is the observational exposure.

Intervention type: DRUG
Intervention: Tenofovir3
Description: receive tenofovir （300mg/d）from （20±2）weeks of pregnancy to one month after delivery, it is the observational exposure.

Intervention type: DRUG
Intervention: Tenofovir4
Description: receive tenofovir （300mg/d）from （20±2）weeks of pregnancy to one week after delivery, it is the observational exposure.
Study: NCT01985295

Intervention type: DRUG
Group type: OTHER
Intervention: pazopanib
Description: A dose escalation trial of Pazopanib, starting at 400mg daily, orally in combination with the standard 25 x 2Gy preoperative radiotherapy in newly diagnosed extremity sarcoma patients. Dose of pazopanib will be escalated via 600mg to maximally 800mg. Overall treatment time of pazopanib is 40 days.
Study: NCT04471077

Intervention type: PROCEDURE
Intervention: bariatric surgery
Description: (Laparoscopic Sleeve Gastrectomy, laparoscopic Roux-en-Y gastric bypass)

Intervention type: PROCEDURE
Intervention: bariatric surgery
Description: (Laparoscopic Sleeve Gastrectomy, laparoscopic Roux-en-Y gastric bypass)
Study: NCT01893541

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ENDOSCOPIC BAND LIGATION
Description: The procedures will be performed using standard technique with a multiband ligation device. Elastic bands will be placed according to physician decision, starting at esophagogastric junction. All varices will be treated during the same session. Endoscopic band ligation sessions will be repeated at intervals of 3 to 4 weeks until all varices will be obliterated.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ENDOSCOPIC BAND LIGATION
Description: The procedures will be performed using standard technique with a multiband ligation device. Elastic bands will be placed according to physician decision, starting at esophagogastric junction. All varices will be treated during the same session. Endoscopic band ligation sessions will be repeated at intervals of 3 to 4 weeks until all varices will be obliterated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PROPRANOLOL
Description: The initial propranolol dose will be orally BID 40 mg, irrespective of patient's weight. The objective of the administration of propranolol will be induce beta-adrenergic blockade evaluated by reduction in heart rate to 55 bpm or a 25% drop in baseline heart rate. A baseline electrocardiogram will be obtained from all patients. The doses will be adjusted during weekly visits until beta-adrenergic blockade. After the adequate dose will be reached, the visits will be scheduled monthly during the first 3 months (until EV eradication) and then at a 3-month interval until the end of follow-up.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: a multiband ligation device
Study: NCT04079439

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physical activity with tailored e-health support
Description: The planned e-health intervention will contain several elements: A motivating smartphone app registers indoor- and outdoor activity as well as activity from the use of an ergometer-bike. For recording of outdoor activity commercial wrist-born accelerometers will be used. The app-solution will be motivating and result in a reward after a predefined level of activity.
Study: NCT01228279

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DIANEAL
Description: Weeks 1 to 6 (6 weeks):~* CAPD (Continuous Ambulatory Peritoneal Dialysis)patients will receive three 4-6 hour dwells of DIANEAL during the day and one 8-10-hour dwell of DIANEAL during the night~* CCPD (Continuous Cycler Peritoneal Dialysis)patients will receive one-two 4-6 hour dwells of DIANEAL during the day and three to seven 2-4-hour dwells of DIANEAL during the night~Weeks 7 to 18 (12 weeks):~\*same regimen as weeks 1 to 6, for both CAPD and CCPD patients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EXTRANEAL
Description: Weeks 1 to 6 (6 weeks):~* CAPD (Continuous Ambulatory Peritoneal Dialysis)patients will receive three 4-6 hour dwells of DIANEAL during the day and one 8-10-hour dwell of DIANEAL during the night~* CCPD (Continuous Cycler Peritoneal Dialysis)patients will receive one-two 8-12-hour dwells of DIANEAL during the day and three to seven 2-4-hour dwells of DIANEAL during the night~Weeks 7 to 18 (12 weeks):~* CAPD (Continuous Ambulatory Peritoneal Dialysis)patients will receive three 4-6 hour dwells of DIANEAL during the day and one 8-10-hour dwell of EXTRANEAL during the night~* CCPD (Continuous Cycler Peritoneal Dialysis)patients will receive one-two 8-12-hour dwells of DIANEAL during the day and one 8-12-hour dwell of EXTRANEAL during the night
Study: NCT00625131

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Delivered through transdermal nicotine patch

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Smoking Cessation
Description: Manualized protocol for CBT in smoking cessation

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Smoking Cessation
Description: Manualized protocol for CBT in smoking cessation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion Sustained Release (SR)
Description: Antidepressant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupropion Sustained Release (SR)
Description: Antidepressant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Description: Pre-treatment placebo transdermal patch
Study: NCT02259647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib 400mg twice daily + intravenous infusion ofVit K1
Description: Sorafenib 400mg twice daily + intravenous infusion ofVit K1 50 mg/day with daily increase of dose by 50 mg for 6 days, followed by oral Vitamin K1 20mg twice daily for 3month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib 400 mg twice daily + Intravenousinfusion of placebo
Description: Sorafenib 400 mg twice daily + Intravenousinfusion ofplacebo daily for 6 days, followed by oral placebo twice daily x 3month
Study: NCT01124110

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Tactics Web-Based Intervention
Description: The Tobacco Tactics Web-Based Intervention contains website, medications, and nurse counseling.

Intervention type: OTHER
Group type: OTHER
Intervention: 1-800-QUIT-NOW Telephone Hotline
Description: The control group receives efficacious smoking cessation treatment via the 1-800-QUIT-NOW telephone hotline. The 1-800-QUIT-NOW hotline is a national program. The first time smokers call the hotline, they receive a personal coach who assists them in setting a quit date and making an individualized quit plan. The personal coach also provides on-going support with up to five telephone coaching sessions around the caller's quit date.
Study: NCT00918281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluciclatide Injection
Description: Fluciclatide Injection (AH111585 (18F) Injection)
Study: NCT02654782

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringer's
Description: Crystalloid fluid given for hemodynamic resuscitation based off of individual patient needs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% Human Albumin
Description: Colloid given for hemodynamic resuscitation based off of individual patient needs.
Study: NCT04321018

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixed meal with medium chain triglycerides
Description: Mixed macronutrient liquid meal (1.6kcal/ml, 15% protein, 47% carbohydrates, 35% fat, 3% fiber) with medium chain triglycerides (3g/100 kcal). An amount with energy supply equivalent to their 50% basal metabolic rate.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mixed meal with medium chain triglycerides
Description: Mixed macronutrient liquid meal (1.6kcal/ml, 15% protein, 47% carbohydrates, 35% fat, 3% fiber) with medium chain triglycerides (3g/100 kcal). An amount with energy supply equivalent to their 50% basal metabolic rate.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixed meal with the replacement of medium chain triglycerides with unsaturated tryglicerides
Description: Mixed macronutrient liquid meal (1.6kcal/ml, 15% protein, 47% carbohydrates, 35% fat, 3% fiber) without medium chain triglycerides (replaced it with long chain triglycerides). An amount with energy supply equivalent to their 50% basal metabolic rate.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mixed meal with the replacement of medium chain triglycerides with unsaturated tryglicerides
Description: Mixed macronutrient liquid meal (1.6kcal/ml, 15% protein, 47% carbohydrates, 35% fat, 3% fiber) without medium chain triglycerides (replaced it with long chain triglycerides). An amount with energy supply equivalent to their 50% basal metabolic rate.
Study: NCT00801736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin, Paclitaxel
Description: * Cisplatin 75mg/m2, Day 1~* Paclitaxel 175mg/m2, Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin, Paclitaxel
Description: * Cisplatin 75mg/m2, Day 1~* Paclitaxel 175mg/m2, Day 1
Study: NCT01743469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasquinimod
Description: 1 capsule: initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5 mg/day or decreasing to 0.25 mg/day after at least 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasquinimod
Description: 1 capsule: initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5 mg/day or decreasing to 0.25 mg/day after at least 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasquinimod
Description: 1 capsule: initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5 mg/day or decreasing to 0.25 mg/day after at least 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasquinimod
Description: 1 capsule: initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5 mg/day or decreasing to 0.25 mg/day after at least 2 weeks.
Study: NCT02782676

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Healon5 OVD
Description: ophthalmic viscosurgical device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Healon5 OVD
Description: ophthalmic viscosurgical device
Study: NCT02787564

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: The intervention consists of providing free fruits and vegetables of the participants' liking for a period of 4 weeks. Each week, a total of 2 portions of either fruits and/or vegetables per day will be provided.
Study: NCT02285855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin treatment given at a dose of 2000 mg by mouth in divided dose daily (500 mg am, 1000 mg noon, 500 mg pm). To reduce GI toxicity, participants start Metformin at 1000 mg daily in a divided dose (500mg am, 500 mg pm) for 1 week.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment given 3 weeks prior to SBRT treatment and for 1 week during SBRT treatment. Placebo administered by mouth three times a day.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Stereotactic body Radiotherapy (SBRT)
Description: SBRT delivered per standard of care practice as determined by participant's physician.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body Radiotherapy (SBRT)
Description: SBRT delivered per standard of care practice as determined by participant's physician.
Study: NCT04662385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aloe vera toothpaste
Description: aloe vera toothpaste have antimicrobial and other multipotential effects.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aloe vera toothpaste
Description: aloe vera toothpaste have antimicrobial and other multipotential effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colgate Total
Description: Whitening toothpaste that removes and prevents new stains Fights bacteria on teeth, tongue, cheeks and gums for whole mouth healthy Mint toothpaste for long lasting fresh breath Helps prevent plaque, tartar, cavities \& gingivitis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colgate Total
Description: Whitening toothpaste that removes and prevents new stains Fights bacteria on teeth, tongue, cheeks and gums for whole mouth healthy Mint toothpaste for long lasting fresh breath Helps prevent plaque, tartar, cavities \& gingivitis
Study: NCT02848820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Augmentin + Gentamicin
Description: Amoxicillin/clavulanic acid (Augmentin) 25/2.5mg 6-hourly (total 100/10 mg/kg daily; maximum 6000/600mg a day) intravenously for 48 hours Oral amoxicillin/clavulanic acid 50/12.5 mg/kg 8-hourly (max 1500/375mg a day) for in total 7 days Gentamicin 7mg/kg once daily for 48 hours

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Appendectomy
Description: Pre-, peri- and postoperative care according to local protocol. No routine postoperative antibiotics
Study: NCT00556569

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHAM JAM
Description: CHAM JAM (previously known as Moving Smart (MS) program) is a daily, 10-minute classroom-based physical activity program led by teachers that integrates academic objectives with physical activity